T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

Create's strategy is not limited to a single cell type. They view success in solid tumors as requiring the programming of all immune cells. Their platform can specifically engineer myeloid cells, T-cells, and NK cells in vivo, orchestrating a coordinated, multi-pronged attack on cancer.

T-cells have natural inhibitory signals, or "brakes" (like PD-1), to prevent over-activation. Some cancers exploit this. Checkpoint inhibitor drugs block these brakes, unleashing a patient's existing T-cells to attack cancer cells more aggressively. This approach has been miraculous for cancers like melanoma.

Unlike inherited DNA, each T-cell creates a unique receptor by randomly recombining DNA segments. This probabilistic process generates a vast diversity of sensors, allowing the immune system to have cells "lying there and waiting" to recognize and combat entirely new viruses or bacteria.

Successful immunotherapies like anti-PD-1 work by shifting the battlefield's arithmetic. They enhance the efficiency of each T-cell, allowing one cell to destroy five or ten cancer cells instead of three. This turns the fight into a 'numbers game' that the immune system can finally win.

A core safety feature of Quell's platform is inserting an extra copy of the FOXP3 gene into its Treg cells. This 'phenotype locks' the cells, anchoring them in a suppressive state. This prevents them from flipping into pro-inflammatory 'attacking' cells, which is critical when they are engineered with a CAR to target specific tissues.

The immune system must balance being aggressive against foreign threats while not attacking the body's own cells. T-cells that recognize "self-antigens" sometimes escape the thymus. Autoimmune diseases emerge when these secondary checks fail, causing the immune system to attack healthy tissues like joints or the brain.

The first successful CAR T-cells targeted CD19, a protein on leukemia cells but also on healthy B-cells. The therapy worked because humans can live without B-cells. This "tolerable collateral damage" was serendipitous and highlights the primary challenge for other cancers: finding targets that won't cause fatal damage to healthy organs.